Ascendis Pharma 株価情報 (NASDAQ: ASND)

Ascendis Pharma (NASDAQ:ASND) 株価情報

ASCENDIS PHARMA A/S - ADR

Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma AS

TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.

News

ASND

Ascendis Submits New Drug Application To FDA For TransCon CNP For Treatment Of Children With Achondroplasia.

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 9.48% since its last report. The company recently reported that it has 4.38 million shares sold short, which is 8.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743002120_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 5.60%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Ascendis Pharma's Recent Short Interest

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 20.52% on an annualized basis producing an average annual return of 31.71%. Currently, Ascendis Pharma has a market capitalization of $10.13 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $6,400.59 today based on a price of $168.50 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742921108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $168 to $200.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $200

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 19.62% on an annualized basis producing an average annual return of 31.01%. Currently, Ascendis Pharma has a market capitalization of $9.09 billion. 
Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741122010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $170 to $200.

Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200

On Wednesday, BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus of 53 cents</a>.
The company reported sales of $747.31 million, beating the consensus of $713.44 million. Total Revenues increased 16% year over year, driven by Voxzogo contributions from new <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43829778/biomarin-reports-fourth-quarter-and-full-year-2024-results-sets-full-year-2025-guidance" rel="noreferrer noopener">patient starts in all regions</a>.
In the quarter, revenues from BioMarin's Enzyme Therapies increased 9%, driven by increased patient demand in all regions and the timing of large government orders in certain regions outside the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43708807/why-is-rare-disease-focused-ascendis-pharma-stock-trading-higher-on-thursday" rel="noreferrer noopener">Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?</a>
Guidance: BioMarin Pharmaceutical expects fiscal year 2025 adjusted EPS of $4.20-$4.40 versus consensus of $3.04. The company expects 2025 sales of $3.1 billion-$3.2 billion versus a consensus of $3.11 billion.
"We expect 2025 to be another year of strong execution and growth in our Skeletal Conditions business unit, led by the continued global expansion of VOXZOGO for achondroplasia&#8230;In summary, we expect continued high performance as we benefit from BioMarin's revamped corporate strategy and operating model in 2025 and beyond," said Alexander Hardy, President and CEO of BioMarin.
In 2025, the company will continue to implement additional components of the $500 million cost transformation program announced in September of 2024, with full realization of benefits expected in 2026.
This ongoing integration of efficiencies in 2025 will enable BioMarin to realize a 40% adjusted operating margin in 2026.
William Blair notes that while BioMarin achieved its financial targets in 2024, its current valuation already accounts for expected revenue growth over the next 12–18 months.
Analyst Sami Corwin sees the limited expansion of Voxzogo's market until 2030–2031, when potential approvals for idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency could broaden its reach. A smaller boost may come in 2027 if its label expands to hypochondroplasia (HCH).
Corwin also flags Ascendis Pharma A/S' (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) navepegritide as a potential challenge for Voxzogo, with a near-term stock overhang as Ascendis moves toward a possible NDA submission in early 2025.
Beyond Voxzogo, BioMarin's enzyme therapy unit provides stable but modest revenue growth, though upcoming competition for Palynziq in 2025 could affect its compound annual growth rate.
Analyst Reaction:
<ul>
<li>BofA Securities maintains BioMarin with a Buy, raising the price target from $99 to $103.</li>
<li>Piper Sandler maintains BioMarin with an Overweight rating while raising the price target from $122 to $126.</li>
</ul>
Price Action: BMRN stock is up 3.19% at $67.70&nbsp;at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43846533/alibaba-q3-earnings-revenue-and-eps-beat-eyes-global-e-commerce-profitability-in-fy25-increase-investments-in-ai" target="_blank" rel="noreferrer noopener">Alibaba Q3 Earnings: Revenue And EPS Beat, Eyes Global E-Commerce Profitability In FY25, Increase Investments In AI</a></li>
</ul>

Analyst Color

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

BMRN

Why Is BioMarin Stock Trading Higher On Thursday?

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 10 years by 42.33% on an annualized basis producing an average annual return of 53.49%. Currently, Ascendis Pharma has a market capitalization of $9.34 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 10 years ago, it would be worth $7,139.06 today based on a price of $156.19 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739977400_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

WIIM

Ascendis Pharma shares are trading higher after Evercore ISI raised its price target on the stock from $220 to $260.

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $220 to $260.

Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $260

On Wednesday, Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported a fourth-quarter EPS loss of 64 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 1.07 euros</a>.
Total revenue for the fourth quarter of 2024 was 173.9 million euros, beating the consensus of 111.178 million euros compared to 137.7 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674382/ascendis-pharma-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">euros reported a year ago</a>.
The increase was primarily due to Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) $100 million upfront fee and the EU launch of Yorvipath.
TransCon hGH (lonapegsomatropin, marketed as Skytrofa) sales reached 58.5 million euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug" rel="noreferrer noopener">Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug</a>
TransCon PTH (palopegteriparatide, marketed as Yorvipath) revenue for the fourth quarter of 2024 totaled €13.6 million.
The company reported a strong start to the U.S. Yorvipath launch, with 908 prescriptions as of February 7, 2025, and 539 unique prescribing health care providers.
As of December 31, 2024, cash and cash equivalents totaled 559.5 million euros. Including the $100 million upfront payment, cash at the end of 2024 would have totaled 655 million euros.
Concurrently, Ascendis Pharma's board authorized the repurchase of up <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674574/ascendis-pharma-as-announces-share-repurchase-program-net-settlement-of-certain-rsus" rel="noreferrer noopener">to $18.25 million shares</a>.
Goldman Sachs analyst writes that Yorvipath has only been available in the U.S. for a few months, but early prescription trends have been strong and widespread. However, insurance coverage and reimbursement challenges may slow revenue growth in the short term.
Looking ahead, analyst Paul Choi writes investors will likely focus on the company's progress toward achieving breakeven cash flow and key milestones, including:
<ul>
<li>The pace of Yorvipath's rollout in the U.S. and EU</li>
<li>Data from the COACH study on achondroplasia, expected in Q2 2025</li>
<li>Regulatory discussions on Transcon CNP</li>
<li>Competitive updates from BioMarin Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) in achondroplasia and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) in hypoparathyroidism.</li>
</ul>
With Yorvipath showing potential for a strong launch in 2025, Goldman Sachs maintains the Buy rating and raises the price target <a target="_blank" href="https://www.benzinga.com/quote/CVS/analyst-ratings" rel="noreferrer noopener">to $225 from $200</a>.
Price Action: ASND stock is up 15.8% at $146.08 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">Zoetis Drops As 2025 Guidance Falls Short Of Estimates</a></li>
</ul>

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Goldman Sachs analyst Paul Choi maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $200 to $225.

Goldman Sachs Maintains Buy on Ascendis Pharma, Raises Price Target to $225

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $167 to $168.

JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $168

Ascendis Pharma shares are trading higher after the company reported better-than-expected Q4 financial results and authorized a share repurchase program worth $18.25 million.

Buybacks

Ascendis Pharma Authorized To Repurchase Up To $18.25M Shares

Earnings Beats

Ascendis Pharma Q4 2024 GAAP EPS €(0.64) Beats €(1.07) Estimate, Sales €173.916M Beat €111.178M Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and maintains $170 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $165 to $167.

JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $167

Press Releases

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Markets

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Comments

Ascendis Pharma

ニュース

パートナーシップ

ベンジンガ・グローバル